Track topics on Twitter Track topics that are important to you
Glycemic control is rapidly restored in patients with insulin resistance after bariatric surgery, in particular after the mal-absorptive one (i.e. Bilio-pancreatic diversion, BPD). To evaluate the mechanisms allowing restoration of insulin sensitivity after BPD the investigators aimed at identifying by using a proteomic approach plasma proteins or peptides that may be involved in the remarkably fast and explicit restoration of insulin sensitivity. In addition to the unbiased proteomics approach, a selection of recognized markers for metabolic control will be measured. These efforts all aim at an increased understanding of how insulin sensitivity is regulated and may provide novel ideas of how to treat insulin resistance and type 2-diabetes.
Study design The study is designed as a single-centre, observational study. The patients will undergo routine analyses usually performed before and after biliopancreatic diversion surgery (BPD), independently of the participation to this specific protocol with the only exception of meal test. Twenty morbidly obese male subjects scheduled for BPD for will be included in the study.
The inclusion and exclusion criteria are set as to create a sufficiently homogenous study population.
As outlined in the study flow chart subjects will be studied and blood samples collected at 3 weeks (+/- 1 week) and 4 days (+/- 1 day) before the day of BPD surgery (baseline-1 and baseline-2), at the day of surgery (day 0), every second day after surgery during the first week (immediate post surgery) as well as two and four weeks after surgery (post surgery-1 and post surgery-2). A deviation of +/- 2 days is allowed for the post surgery-1 and post surgery-2 visits.
All fasting samples are obtained in the morning after an overnight fast (12 h). Immediate post surgery (fasting) samples will be collected after 12 h rest from parenteral nutrition from the arm not used for nutritional substitution during the first 4 days after surgery (when parenteral nutrition is given). The immediate post surgery (fasting) samples obtained from day 5 and forward after surgery, when subjects have started to eat, will be obtained in the morning after an overnight fast (12 h). Nutrient stimulation samples will be obtained at baseline-1 and 2 and post surgery-1 and 2 after intake of a test meal. A complete list of all procedures for each visit is provided in Table 1 and an overview of all planned blood samples, including volumes and purpose is provided in Table 2. Motivations for the collection of various samples are provided under section 10.3.1 "Proteomics analysis, experimental design issues".
In case of discontinuation, additional subjects should be enrolled such that a complete set of samples from no less than 20 subjects can be obtained.
Target subject population Inclusion criteria
- Morbidly obese male with a BMI >40 kg/m2 who, for their obesity disease, are eligible for bariatric surgery and have accepted to undergo BPD
- Confirmed insulin resistance; fasting serum insulin level > 60 pmol/L
- Age 25-55 years
- Weight stable for at least 6 months before the study (+/- 5 kg within the previous 6 months)
- Stable medication
- Provision of informed consent, statistical analysis, and publications of obtained results Exclusion criteria
- Patients not eligible for BPD
- Incapacity to give a valid informed consent or unwilling to give the consent
- Patients eligible for BPD, but with:
- Type 2-diabetes mellitus
- Significant illness within the two weeks preceding surgery, as judged by the physician.
- Obvious infection (bacteria, virus etc)
- Major cardiovascular disease
- Major gastrointestinal, respiratory, or any hormonal disorders
- Medication affecting lipid metabolism within 3 months of the study
- History of drug addiction and/or alcohol use
- Suspected or confirmed poor compliance
- Exercise +/-3 times a week
- Blood donation within 12 weeks preceding screening visit
Observational Model: Case-Only, Time Perspective: Prospective
Day Hospital of Metabolic Diseases, Catholic University
Catholic University of the Sacred Heart
Published on BioPortfolio: 2014-07-23T21:08:40-0400
A Prospective Double-Blinded, Placebo Controlled, Randomized Trial comparing a single dose of Vitamin D (Colecalciferol) 300.00UI to placebo on patients with insulin resistance. Primary Ou...
The literature suggests that there may be an association between hepatitis C and type 2 diabetes mellitus independent of the presence of cirrhosis, the likely mechanism for which is insuli...
This study aims to elucidate the role of the microcirculation in the development of whole body insulin resistance. The investigators hypothesize that impaired insulin signaling in the vasc...
Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using nonconcentrated forms of insulin (U100 ...
This research is to investigate the nutritional supplement chromium picolinate. A large number of people use chromium picolinate from health food stores to improve the function of the hor...
Insulin resistance, defined as attenuated sensitivity responding to insulin, impairs insulin action. Direct causes and molecular mechanisms of insulin resistance have thus far remained elusive. Here w...
Insulin resistance is a major pathogenic hallmark of impaired glucose metabolism. We assessed the accuracy of insulin resistance and cut-off values using homeostasis model assessment of insulin resist...
A reduction in insulin-stimulated glucose uptake in skeletal muscles is a characteristic of insulin resistance and type 2 diabetes mellitus (T2DM). The glucagon-like peptide (GLP)-1 agonist liraglutid...
Obesity is tightly linked to hepatic steatosis and insulin resistance. One feature of this association is the paradox of selective insulin resistance: insulin fails to suppress hepatic gluconeogenesis...
Insulin resistance, a common feature of metabolic disorders such as obesity, nonalcoholic fatty liver disease, metabolic syndrome, and polycystic ovary syndrome, is a risk factor for development of di...
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)
THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
Rare autosomal recessive syndrome of extreme insulin resistance due to mutations in the binding domain of INSULIN RECEPTOR. Clinical features include severe intrauterine and postnatal growth restriction, characteristic dysmorphic FACIES; HIRSUTISM; VIRILIZATION; multiple endocrine abnormalities, and early death.
An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake. Diagnosis is based on clinical presentation...